Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
passiflora
- Development stage
- Unknown
- Lead developer
- MR Pharma
- Administration
- Oral
01
Overview
Passiflora, in the context of the Millet Roux clinical program, refers to the herbal combination product commercially known as Passiflorine. This formulation is primarily indicated for the treatment of generalized anxiety disorder (GAD) and related sleep disturbances. The product consists of an association of three plant extracts: *Passiflora incarnata* (passionflower), *Crataegus oxyacantha* (hawthorn), and *Salix alba* (white willow). *Passiflora incarnata* is the primary active component, exerting anxiolytic and sedative effects through the modulation of the gamma-aminobutyric acid (GABA) system, specifically acting as a positive allosteric modulator of GABA-A receptors. *Crataegus oxyacantha* contributes mild sedative and cardiovascular-stabilizing properties, while *Salix alba* (containing salicin) provides mild anti-inflammatory and analgesic support. The combination has been evaluated in Phase III clinical trials and is approved for use in certain regions, such as Brazil, as a phytotherapeutic medicine for anxiety management.
- Brand names
- Passiflorine
- Other names
- passionflowerPassiflora incarnataPassiflora association
02
Targets
GABRR (GABA-A receptor subunit rho)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)GAT (GABA transporter family)PGHS-1 (Prostaglandin G/H Synthase 1)GABA-B (Gamma-aminobutyric acid receptor type B)
Beyond the preview
Go deeper on passiflora.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on passiflora.